Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Perampanel in Idiopathic Generalized Epilepsy

Does it reduce PGTC seizures?

Publish date:: August 25, 2015

Adjunctive perampanel reduces primary, generalized tonic-clonic (PGTC) seizure frequency, compared with placebo, in patients with drug-resistant PGTC seizures in idiopathic generalized epilepsy (IGE), according to a study of 162 patients aged 12 years and older with PGTC and IGE. Researchers found:

• Compared to placebo (-38.4%), perampanel (-76.5%) conferred a greater median percent change in seizure frequency per 28 days.

• Perampanel (64.2%) conferred greater 50% PGTC seizure responder rate than placebo (39.5%).

• During maintenance, 12.3% of placebo-treated patients and 30.9% of perampanel-treated patients achieved PGTC seizure freedom.

• The most frequent treatment-emergent adverse events with perampanel were dizziness (32.1%) and fatigue (14.8%).

Citation: French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. [Published online ahead of print August 21, 2015]. Neurol. doi: http://dx.doi.org/10.1212/WNL.0000000000001930.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Epilepsy & Seizures

Study supports halting antiseizure medications after neonatal seizures,

CBD for LGS: Fewer seizures, but thrombocytopenia risk,

Preventive treatment delays first seizure onset in tuberous sclerosis complex,

Listening to Mozart helps tame epilepsy,

In epilepsy, brain-responsive stimulation passes long-term tests,